Apigenomics AG gives mandatory convertible bonds in full amount of EUR 5.5 million on 27 January 2021

Not for publication, in distribution or distribution or with the United States of America, Canada, Japan and Austria.

Publication of inside information as per Article 17 March

Epigenomics AG holds mandatory convertible bonds in the full amount of EUR 5.5 million

Berlin, January 27, 2021 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; “Company”) has today successfully completed the appointment of subordinate compulsory convertible bonds, the issue of which was decided by the company’s Board of Management with approval on January 7, 2021 Was. Supervisory Board. In total, the compulsory convertible bonds were held in full, with a total nominal amount of EUR 5,500,000.00. The proposal was clearly seen. Mandatory convertible bonds consist of 500,000 bonds that can be converted into 5,000,000 registered shares in the company. The gross issue increases to EUR 5.5 million from the issue of the compulsory convertible bond amount.

Full terms and conditions are available on the Epigenomics AG website www.epigenomics.com/de/wandelanleihe/ available.

Contact:
The companies
Epigenomics AG, Genestra 5, 10829 Berlin
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, Email: [email protected]

Investor Relations
IR.on AG, Frederick Hilke, Fabian Kirchman, tel +49 221 9140 970, e-mail: [email protected]

Important instructions

This publication has neither an offer to sell nor an invitation to purchase or subscribe to securities. In particular, the formation of this publication is neither an offer to sell nor a request for an offer to purchase securities in the United States, which does not refer to securities. Shall not be registered under the US Securities Act of 1933, as amended (“Securities Act”) or state law, and may not be registered in the United States or “American Persons” (as in Regulation S. of the Securities Act Is defined)) or for the account of “American persons”, unless they are exempted or exempted from registration under the Securities Act and US state law. This publication and the information contained therein may not be distributed or transmitted to the United States or other jurisdictions wherein the public offering or sale of securities is prohibited and may not be distributed through “American persons” or publications with general distribution Is United States. There is no public offering of shares in the United States. Subject to certain exceptions, the securities mentioned in this declaration may not be sold or offered for sale in Australia, Canada or Japan, or in the account of Australian, Canadian or Japanese residents. There is no registration of the securities named in this declaration according to the respective legal requirements in Australia, Canada and Japan.

Pay attention to further statements

Explicitly or explicitly this publication contains forward-looking details about Epigenomics AG and its business activities. These statements include certain known and unknown risks, uncertainties, and other factors that may reflect actual results, financial condition and Epigenomics AG’s performance differently from potential outcomes or performance, which are clear or unambiguous in such statements Were expressed in form. Epigenomics is making this announcement as of today’s publication and does not intend to update any forward-looking details contained in it due to new information or future events or any other reason.